POZEN Inc. (NASDAQ: POZN) announced that it has resubmitted the New Drug Application (NDA) for PA8140/PA32540 to the U.S. Food ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE